The
carbapenems are
beta-lactam-type
antibiotics with an exceptionally broad spectrum of activity.
Ertapenem is a new
carbapenem developed to address the pharmacokinetic shortcomings (short half-life) of
imipenem and
meropenem.
Ertapenem shares similar structural features with
meropenem, including its stability to dehydropeptidase-1, allowing it to be administered without a dehydropeptidase-1 inhibitor.
Ertapenem, like
imipenem and
meropenem, demonstrates broad-spectrum antimicrobial activity against many Gram-positive and -negative aerobes and anaerobes and is resistant to nearly all
beta-lactamases, including extended-spectrum
beta-lactamases and AmpCs. However, it differs from both
imipenem and
meropenem in demonstrating limited activity against Enterococcusspp., Pseudomonasaeruginosa and other nonfermentative Gram-negative bacteria commonly associated with
nosocomial infections. The extensive protein binding of
ertapenem extends the half-life and allows for once-daily dosing. Prospective, multicenter, randomized, double-blind, comparative clinical studies demonstrate similar clinical efficacy of
ertapenem compared with other agents. Clinical trials of complicated
intra-abdominal infection, acute
pelvic infection, complicated skin and soft-structure
infection, community-acquired pneumonia and complicated
urinary tract infections demonstrated that
ertapenem has equivalent efficacy and safety compared with
ceftriaxone and
piperacillin/tazobactam.
Ertapenem is a promising new
carbapenem with excellent efficacy and safety for the treatment of a variety of
community-acquired infections. It also appears to be of great value as an outpatient parenteral antimicrobial
therapy.